Achillion Pharmaceuticals (ACHN): Price Target and June Short Interest Disclosure

Achillion Pharmaceuticals (ACHN) : 7 investment research analysts covering Achillion Pharmaceuticals (ACHN) have an average price target of $10 for the near short term. The highest target price given by the Brokerage Firm to the stock is $16 and the lowest target is $7 for the short term. Analysts expect the variance to be within $3.37 of the average price.

Achillion Pharmaceuticals (ACHN) has shown a drop of 9.8% or 1,515,274 shares in the short positions. The bets have increased to 13,966,008 shares on June 30,2016 from 15,481,282 shares on June 15,2016. With respect to the floated shares, the shorts are 12.3%. The days to cover are calculated to be 9, using the standard per day volume of 1,542,810 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.

Also, Brokerage firm JMP Securities upgrades its rating on Achillion Pharmaceuticals (NASDAQ:ACHN). The shares have been rated Market Outperform. Previously, the analysts had a Market Perform rating on the shares. The rating by the firm was issued on July 7, 2016.


Achillion Pharmaceuticals (NASDAQ:ACHN): On Thursdays trading session , Opening price of the stock was $8.54 with an intraday high of $8.75. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $8.405. However, the stock managed to close at $8.64, a loss of 3.25% for the day. On the previous day, the stock had closed at $8.93. The total traded volume of the day was 2,453,128 shares.

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Companys primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.